Apatinib Plus Concurrent Neoadjuvant Chemoradiotherapy for Gastroesophageal Junction

Gastroesophageal Junction Adenocarcinoma Clinical Trial

Official title:

Prospective, Randomized, Controlled, Multicenter, Phase III Study of Apatinib Plus Concurrent Neoadjuvant Chemoradiotherapy for Siewert II ，III of Locally Advanced HER-2 Negative Adenocarcinoma at Gastroesophageal Junction

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03986385
• Other study ID #: HRA-G04
• Status: Recruiting
• Phase: Phase 3
• Start date: June 1, 2019
• Est. completion date: January 31, 2021

Study information

• Verified date: February 2020
• Source: Hebei Medical University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to assess the efficacy and safety of patients who receive concurrent neoadjuvant chemoradiotherapy for Siewert II ，III of locally advanced HER-2 negative adenocarcinoma at gastroesophageal junction.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 180
• Est. completion date: January 31, 2021
• Est. primary completion date: June 30, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

1. Adult patients (18 to 70 years old) at the time of voluntarily signing informed consent;

2. Histologically or cytologically confirmed adenocarcinoma. The her-2 negative was detected by immunohistochemistry or fluorescence in situ hybridization;

3. Con?rmed to Siewert II , III of locally advanced adenocarcinoma at gastroesophageal junction and tumor long diameter =8 cm by gastroscopy;

4. Patients with Stage for ? by CT/MRI (According to the eighth edition of AJCC );

5. Patients with measurable lesions(measuring=10mm on spiral CT scan, satisfying the criteria in RECIST1.1);

6. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1;

7. Life expectancy greater than or equal to 6 months;

8. Subject must meet all of the following criteria based on the laboratory tests within 14 days prior to the first dose of study treatment.

(1) Baseline blood indicators meet the following criteria:HB=80g/L;ANC=1.5×109/L;PLT=90×109/L;WBC=4.0×109/L and =15×109/L (2) Baseline biochemical indicators meet the following criteria: ALT and AST=2.5ULN, but<=5ULN if the transferanse elevation is due to liver metastases; ALP=2.5ULN;TBiL=1.5ULN;Cr=1.5ULN,Endogenous creatinine clearance rate ?60 ml/min (Cockcroft-Gault formula);APTT=1.5ULN,and INR or PT=1.5ULN.

9.Women of childbearing age must have contraceptive measures or have test pregnancy (serum or urine) enroll the study before 7 days, and the results must be negative, and take the methods of contraception during the test and the last to have drugs after 8 weeks. Men must be contraception or has sterilization surgery during the test and the last to have drugs after 8 weeks; 10.Participants were willing to join in this study, and written informed consent, good adherence, cooperate with the follow-up.

Exclusion Criteria:

1. Allergic to apatinib, capecitabine and oxaliplatin;

2. The cytological examination of the abdominal cavity washing fluid showed that the tumor shedding cells were positive;

3. Have high blood pressure and antihypertensive drug treatment can not control (systolic blood pressure > 140 mmHg,diastolic blood pressure > 90 mmHg),Uncontrolled coronary heart disease and arrhythmia,class?-?cardiac insufficiency;

4. A variety of factors influencing oral drugs (such as unable to swallow, nausea,vomiting,chronic diarrhea and intestinal obstruction, etc);

5. Patients with tendency of gastrointestinal bleeding, including the following:a local active ulcerative lesions,and defecate occult blood;Has melena and hematemesis in two months;

6. Coagulant function abnormality (INR > 1.5 ULN, APTT > 1.5 ULN), with bleeding tendency;

7. Pregnant or lactating women;

8. Patients with other malignant tumors within 5 years (except for curable skin basal cell carcinoma and cervical carcinoma in situ);

9. History of psychiatric drugs abuse and can't quit or patients with mental disorders;

10. Less than 4 weeks from the last clinical trial;

11. The researchers think inappropriate.

Related Conditions & MeSH terms

• Adenocarcinoma
• Gastroesophageal Junction Adenocarcinoma

Intervention

Drug:
• Apatinib Capecitabine Oxaliplatin
apatinib 250mg qd po q4w Capecitabine 1000mg/m2 bid d1-14,Oxaliplatin 130 mg/m2 Ivgtt d1 q3w
• Capecitabine Oxaliplatin
Preoperative: Capecitabine 1000mg/m2 bid d1-14,Oxaliplatin 130 mg/m2 Ivgtt d1 q3w

Locations

Country	Name	City	State
China	QunZhao	Shijia Zhuang	Hebei

Sponsors (1)

Lead Sponsor	Collaborator
Hebei Medical University

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The pathological complete response rate(pCR)	The lesion disappeared completely by pathology	[ Time Frame: within 3 weeks after surgery ]
Primary	Disease-free survival(DFS)	Baseline to measured date of recurrence or death from any cause	[ Time Frame: 3 year ]
Secondary	Objective response rate (ORR)	Baseline to measured stable disease	[ Time Frame: Preoperative ]
Secondary	Disease Control Rate(DCR)	Baseline to measured disease progression	[ Time Frame: Preoperative ]
Secondary	R0-resection rate	There was no residual by the microscope	[ Time Frame: within 3 weeks after surgery ]
Secondary	Overall survival (OS)	Baseline to measured date of death from any cause	[ Time Frame: 3years ]